Theresa Westphal1,2, Simon P Gampenrieder1,2,3, Gabriel Rinnerthaler1,2,3, Marija Balic4, Florian Posch4, Nadia Dandachi4, Cornelia Hauser-Kronberger5, Roland Reitsamer6, Karl Sotlar5, Bianca Radl1,2, Christoph Suppan4, Herbert Stöger4, Richard Greil1,2,3. 1. IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria. 2. Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Salzburg, Austria. 3. Cancer Cluster Salzburg, Salzburg, Austria. 4. Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. 5. Pathologic Institute of the University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria. 6. University Clinic for Special Gynecology of the University Hospital Salzburg, Paracelsus Medical University Salzburg, Salzburg, Austria.
Abstract
Background: For hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC), adjuvant chemotherapy (ACT) is recommended in the case of high-risk features only. The MINDACT trial showed that patients with high clinical risk (CR) but low genomic risk (GR) defined by the 70-gene signature (MammaPrint®; 70-GS) did not benefit from ACT. In this registry, we investigated the frequency and feasibility of 70-GS and concurrent 80-gene subtyping (BluePrint®) use in HR-positive, HER2-negative EBC. Furthermore, we recorded the frequency of ACT recommendation and the adherence to it when the "MINDACT strategy" was used. Methods: This prospective registry included patients from 2 Austrian cancer centers. Similar to MINDACT, a modified version of Adjuvant!Online was used to determine CR, and 70-GC was used to determine GR in high-CR patients. ACT was recommended to patients with high CR and high GR. Results: Of 224 enrolled patients, 76 (33.9%) had high CR and 67 (88.2%) received genomic testing. Of those, 43 (64.2%) were classified as low and 24 (35.8%) as high GR, respectively. All 24 patients with high CR and GR (10.7% of all patients) received the recommendation for ACT, but ACT was started in only 15 patients (62.5%). The median time from surgery to the start of ACT was 45 days (range 32-68), and the median time from test decision to the test result was 15 days (range 9-56). Conclusion: We showed that the results of the MINDACT trial are reproducible in an Austrian population. Incorporating 70-GS into the daily clinical routine is feasible and mostly accepted by physicians for the guidance of treatment recommendations.
Background: For hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC), adjuvant chemotherapy (ACT) is recommended in the case of high-risk features only. The MINDACT trial showed that patients with high clinical risk (CR) but low genomic risk (GR) defined by the 70-gene signature (MammaPrint®; 70-GS) did not benefit from ACT. In this registry, we investigated the frequency and feasibility of 70-GS and concurrent 80-gene subtyping (BluePrint®) use in HR-positive, HER2-negative EBC. Furthermore, we recorded the frequency of ACT recommendation and the adherence to it when the "MINDACT strategy" was used. Methods: This prospective registry included patients from 2 Austrian cancer centers. Similar to MINDACT, a modified version of Adjuvant!Online was used to determine CR, and 70-GC was used to determine GR in high-CR patients. ACT was recommended to patients with high CR and high GR. Results: Of 224 enrolled patients, 76 (33.9%) had high CR and 67 (88.2%) received genomic testing. Of those, 43 (64.2%) were classified as low and 24 (35.8%) as high GR, respectively. All 24 patients with high CR and GR (10.7% of all patients) received the recommendation for ACT, but ACT was started in only 15 patients (62.5%). The median time from surgery to the start of ACT was 45 days (range 32-68), and the median time from test decision to the test result was 15 days (range 9-56). Conclusion: We showed that the results of the MINDACT trial are reproducible in an Austrian population. Incorporating 70-GS into the daily clinical routine is feasible and mostly accepted by physicians for the guidance of treatment recommendations.
Authors: Anna Sapino; Paul Roepman; Sabine C Linn; Mireille H J Snel; Leonie J M J Delahaye; Jeroen van den Akker; Annuska M Glas; Iris M Simon; Neil Barth; Femke A de Snoo; Laura J van 't Veer; Luca Molinaro; Els M J J Berns; Jelle Wesseling; Lee B Riley; David Anderson; Bichlien Nguyen; Charles E Cox Journal: J Mol Diagn Date: 2013-12-28 Impact factor: 5.568
Authors: Anne-Vibeke Lænkholm; Maj-Britt Jensen; Jens Ole Eriksen; Birgitte Bruun Rasmussen; Ann S Knoop; Wesley Buckingham; Sean Ferree; Carl Schaper; Torsten O Nielsen; Taryn Haffner; Torben Kibøl; Maj-Lis Møller Talman; Anne Marie Bak Jylling; Tomasz Piotr Tabor; Bent Ejlertsen Journal: J Clin Oncol Date: 2018-01-25 Impact factor: 44.544
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: R Torrisi; C A Garcia-Etienne; A Losurdo; E Morenghi; L Di Tommaso; W Gatzemeier; A Sagona; B Fernandes; C Rossetti; M Eboli; A Rubino; E Barbieri; C Andreoli; S Orefice; C Gandini; S Rota; M Zuradelli; G Masci; A Santoro; C Tinterri Journal: Breast Date: 2013-05-03 Impact factor: 4.380
Authors: Brett Wallden; James Storhoff; Torsten Nielsen; Naeem Dowidar; Carl Schaper; Sean Ferree; Shuzhen Liu; Samuel Leung; Gary Geiss; Jacqueline Snider; Tammi Vickery; Sherri R Davies; Elaine R Mardis; Michael Gnant; Ivana Sestak; Matthew J Ellis; Charles M Perou; Philip S Bernard; Joel S Parker Journal: BMC Med Genomics Date: 2015-08-22 Impact factor: 3.063
Authors: Ralf Kronenwett; Kerstin Bohmann; Judith Prinzler; Bruno V Sinn; Franziska Haufe; Claudia Roth; Manuela Averdick; Tanja Ropers; Claudia Windbergs; Jan C Brase; Karsten E Weber; Karin Fisch; Berit M Müller; Marcus Schmidt; Martin Filipits; Peter Dubsky; Christoph Petry; Manfred Dietel; Carsten Denkert Journal: BMC Cancer Date: 2012-10-05 Impact factor: 4.430